Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

  • Topic prioritisation

Documents

Documents created during the development process.

Declaration of interests

Invitation to participate